Roivant Sciences (ROIV) fundamentals: P/E, valuation, undervalued?
Roivant Sciences · Health Care · ref. ETF XLV · price $33.35
In short — Roivant Sciences trades at —× earnings (P/E), -19.4× forward, with a net margin of 0.0 % and revenue growth of -34 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Roivant Sciences stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$33.35+103.4% over range
Oct 14, 25low $16.4 · high $41.81Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
86% recommend buying · 7 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
-19.4
Forward P/E
—
PEG
5.7
Price/book (P/B)
$24.1B
Market cap
-0.51
EPS
Profitability & growth
0.0 %
Net margin
-34 %
Revenue growth
—
Earnings growth
$107M
Total debt
Roivant Sciences income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $61M | $-1.0B | -1646.6 % |
| 2024 | $125M | $4.3B | 3484.9 % |
| 2025 | $29M | $-172M | -592.0 % |
| 2026 | $8M | $-300M | -3629.2 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Roivant Sciences's P/E and is the stock undervalued? What's a good P/E?
Roivant Sciences's P/E is — (forward -19.4). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Roivant Sciences profitable?
Roivant Sciences has a net margin of 0.0 % (EPS -0.51). The company is not (yet) profitable.
Is ROIV stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Roivant Sciences? The JPI assistant answers using our backtest data.
Keep exploring Roivant Sciences